Pharmaceutical Executive
Science deserves all the credit it gets, and more, for driving this industry. Still, no science succeeds without a certain application of what we broadly call art. Inside the scientific discipline, many arts apply-the art of experiment, the art of planning, and the art of free association among them.
Science deserves all the credit it gets, and more, for driving this industry. Still, no science succeeds without a certain application of what we broadly call art. Inside the scientific discipline, many arts apply-the art of experiment, the art of planning, and the art of free association among them.
Although the human brain invented science, it has never surrendered fully to its constraint. That may be because one lobe wants to embrace the discipline, and the other wants to fight or flee it. However much we depend on the mathematical rigor of the scientific mind, we cling to the mysterious spontaneity of the human imagination.
Our bicameral brain may also account for the popular dichotomy of science and art. Physics is a science; cooking is an art-and so on. Yet artists have used and reflected science since its inception. And scientists have explored the universe in artful and ingenious ways, relying often on their creative side for turning data into theory, and theory into technology.
But don't tell that to a scientist or an artist-unless you like being put in your place. In method and self-image, scientists and artists tend to follow quite different personal paths. If they share anything, it is their professional disdain for dilettantes who dare compare science and art. And I'm just getting started making such unsanctioned comparisons.
Imagine what would happen if something compelled artists and scientists to integrate their disciplines for some grand enterprise of critical importance to the world. Now take it a step further: Suppose that not only artists but also many other subcultures-lawyers, accountants, business and marketing execs, and so on-had to "hang" with the scientific community, and with each other, for the common good. That, in a nutshell, is the pharmaceutical industry.
It is also a broad hint at why the industry's science-to-business continuum has so many discontinuities. Terms like "cross functional-fertilization" and "interdisciplinary teams" have such a comforting ring to them, just saying them seems to guarantee success. But however rational and appealing the philosophy behind such terms, people can find amazingly creative ways to defeat it. Tough mergers like Aventis amplified cross-functional dissonance. Many others, like Merck, see the effect over longer periods, ending in disappointing pipelines.
Why would anyone want to resist a more harmonious system? Not always for the best of reasons-and not always for the worst. Some people always fight change; others embrace it too easily. Most of us stand between those extremes. We don't like being forced into things, but we respond to appeals for the higher good, as long as it doesn't require the destruction of what makes us individuals. Wise management-an art or a science?-will make better progress toward cross-disciplinary cooperation by applying that simple insight.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
FDA Approves Amgen’s Lumakras Plus Vectibix for KRAS G12C-Mutated Metastatic Colorectal Cancer
January 20th 2025Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and Vectibix significantly improved progression-free survival in patients with KRAS G12C-mutated metastatic colorectal cancer.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.